These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16548791)

  • 1. Oritavancin--an investigational glycopeptide antibiotic.
    Ward KE; Mersfelder TL; LaPlante KL
    Expert Opin Investig Drugs; 2006 Apr; 15(4):417-29. PubMed ID: 16548791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oritavancin: an investigational lipoglycopeptide antibiotic.
    Karaoui LR; El-Lababidi R; Chahine EB
    Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Stumpo C; Rybak MJ
    J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oritavancin for acute bacterial skin and skin structure infections.
    Messina JA; Fowler VG; Corey GR
    Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational new drugs for the treatment of resistant pneumococcal infections.
    Hoffman-Roberts HL; C Babcock E; Mitropoulos IF
    Expert Opin Investig Drugs; 2005 Aug; 14(8):973-95. PubMed ID: 16050791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.
    Guay DR
    Pharmacotherapy; 2004 Jan; 24(1):58-68. PubMed ID: 14740788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
    Crandon J; Nicolau DP
    Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oritavancin: a long-acting antibacterial lipoglycopeptide.
    Kaasch AJ; Seifert H
    Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
    Henson KE; Levine MT; Wong EA; Levine DP
    Expert Rev Anti Infect Ther; 2015; 13(10):1265-78. PubMed ID: 26165756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oritavancin: mechanism of action.
    Zhanel GG; Schweizer F; Karlowsky JA
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S214-9. PubMed ID: 22431851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oritavancin: A Novel Lipoglycopeptide.
    Mattox J; Belliveau P; Durand C
    Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
    Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.